vs

Side-by-side financial comparison of Cardlytics, Inc. (CDLX) and Liquidia Corp (LQDA). Click either name above to swap in a different company.

Liquidia Corp is the larger business by last-quarter revenue ($92.0M vs $50.9M, roughly 1.8× Cardlytics, Inc.). On growth, Liquidia Corp posted the faster year-over-year revenue change (3054.6% vs -25.5%). Liquidia Corp produced more free cash flow last quarter ($42.2M vs $13.0M).

Cardlytics is a leading purchase intelligence and advertising platform that partners with major banks to analyze anonymized consumer transaction data. It delivers targeted, performance-driven ad campaigns for consumer brands, retailers and service providers, helping advertisers reach audiences based on real purchase behavior, with core operations across North America and the United Kingdom.

Liquidia Corp is a late-stage biopharmaceutical firm focused on developing and commercializing innovative inhaled therapies for respiratory and rare diseases. It uses its proprietary PRINT particle engineering tech to create optimized drug products, with core markets in North America covering pulmonary arterial hypertension and asthma indications.

CDLX vs LQDA — Head-to-Head

Bigger by revenue
LQDA
LQDA
1.8× larger
LQDA
$92.0M
$50.9M
CDLX
Growing faster (revenue YoY)
LQDA
LQDA
+3080.1% gap
LQDA
3054.6%
-25.5%
CDLX
More free cash flow
LQDA
LQDA
$29.2M more FCF
LQDA
$42.2M
$13.0M
CDLX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CDLX
CDLX
LQDA
LQDA
Revenue
$50.9M
$92.0M
Net Profit
$14.6M
Gross Margin
Operating Margin
-12.0%
21.5%
Net Margin
15.8%
Revenue YoY
-25.5%
3054.6%
Net Profit YoY
137.9%
EPS (diluted)
$-0.15
$0.18

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CDLX
CDLX
LQDA
LQDA
Q4 25
$50.9M
$92.0M
Q3 25
$47.0M
$54.3M
Q2 25
$58.0M
Q1 25
$56.4M
Q4 24
$68.3M
Q3 24
$61.1M
Q2 24
$64.0M
Q1 24
$62.2M
Net Profit
CDLX
CDLX
LQDA
LQDA
Q4 25
$14.6M
Q3 25
$-72.7M
$-3.5M
Q2 25
$-9.3M
Q1 25
$-13.3M
Q4 24
Q3 24
$-145.2M
Q2 24
$-4.3M
Q1 24
$-24.3M
Operating Margin
CDLX
CDLX
LQDA
LQDA
Q4 25
-12.0%
21.5%
Q3 25
-146.6%
3.3%
Q2 25
-22.0%
Q1 25
-24.9%
Q4 24
-12.2%
Q3 24
-243.1%
Q2 24
-24.7%
Q1 24
-36.7%
Net Margin
CDLX
CDLX
LQDA
LQDA
Q4 25
15.8%
Q3 25
-154.7%
-6.5%
Q2 25
-16.0%
Q1 25
-23.5%
Q4 24
Q3 24
-237.6%
Q2 24
-6.7%
Q1 24
-39.0%
EPS (diluted)
CDLX
CDLX
LQDA
LQDA
Q4 25
$-0.15
$0.18
Q3 25
$-1.36
$-0.04
Q2 25
$-0.18
Q1 25
$-0.26
Q4 24
$-0.36
Q3 24
$-2.90
Q2 24
$-0.09
Q1 24
$-0.56

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CDLX
CDLX
LQDA
LQDA
Cash + ST InvestmentsLiquidity on hand
$48.7M
$190.7M
Total DebtLower is stronger
$212.6M
Stockholders' EquityBook value
$-6.5M
$44.7M
Total Assets
$285.6M
$327.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CDLX
CDLX
LQDA
LQDA
Q4 25
$48.7M
$190.7M
Q3 25
$44.0M
$157.5M
Q2 25
$46.7M
Q1 25
$52.0M
Q4 24
$65.6M
Q3 24
$67.0M
Q2 24
$71.2M
Q1 24
$97.8M
Total Debt
CDLX
CDLX
LQDA
LQDA
Q4 25
$212.6M
Q3 25
$214.6M
Q2 25
$214.3M
Q1 25
$213.9M
Q4 24
$213.6M
Q3 24
$213.2M
Q2 24
$212.9M
Q1 24
$257.9M
Stockholders' Equity
CDLX
CDLX
LQDA
LQDA
Q4 25
$-6.5M
$44.7M
Q3 25
$-4.7M
$22.1M
Q2 25
$58.7M
Q1 25
$64.1M
Q4 24
$70.0M
Q3 24
$69.7M
Q2 24
$210.0M
Q1 24
$199.1M
Total Assets
CDLX
CDLX
LQDA
LQDA
Q4 25
$285.6M
$327.9M
Q3 25
$292.8M
$276.0M
Q2 25
$361.1M
Q1 25
$369.1M
Q4 24
$392.7M
Q3 24
$399.4M
Q2 24
$534.4M
Q1 24
$569.0M
Debt / Equity
CDLX
CDLX
LQDA
LQDA
Q4 25
Q3 25
Q2 25
3.65×
Q1 25
3.34×
Q4 24
3.05×
Q3 24
3.06×
Q2 24
1.01×
Q1 24
1.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CDLX
CDLX
LQDA
LQDA
Operating Cash FlowLast quarter
$13.0M
$44.2M
Free Cash FlowOCF − Capex
$13.0M
$42.2M
FCF MarginFCF / Revenue
25.5%
45.9%
Capex IntensityCapex / Revenue
0.0%
2.2%
Cash ConversionOCF / Net Profit
3.04×
TTM Free Cash FlowTrailing 4 quarters
$8.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CDLX
CDLX
LQDA
LQDA
Q4 25
$13.0M
$44.2M
Q3 25
$1.8M
$-9.8M
Q2 25
$1.2M
Q1 25
$-6.7M
Q4 24
$3.0M
Q3 24
$1.4M
Q2 24
$4.4M
Q1 24
$-17.6M
Free Cash Flow
CDLX
CDLX
LQDA
LQDA
Q4 25
$13.0M
$42.2M
Q3 25
$1.7M
$-10.7M
Q2 25
$903.0K
Q1 25
$-6.8M
Q4 24
$2.9M
Q3 24
$878.0K
Q2 24
$4.1M
Q1 24
$-18.3M
FCF Margin
CDLX
CDLX
LQDA
LQDA
Q4 25
25.5%
45.9%
Q3 25
3.7%
-19.7%
Q2 25
1.6%
Q1 25
-12.1%
Q4 24
4.2%
Q3 24
1.4%
Q2 24
6.5%
Q1 24
-29.4%
Capex Intensity
CDLX
CDLX
LQDA
LQDA
Q4 25
0.0%
2.2%
Q3 25
0.0%
1.7%
Q2 25
0.6%
Q1 25
0.2%
Q4 24
0.2%
Q3 24
0.8%
Q2 24
0.4%
Q1 24
1.0%
Cash Conversion
CDLX
CDLX
LQDA
LQDA
Q4 25
3.04×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons